Ghosh Laskar Sarbani, Kumar Anuj, Adhau Ashwini, Sinha Shwetabh, Mohanty Samarpita, Bal Munita, Mittal Neha, Rane Swapnil, Patil Asawari, Budrukkar Ashwini, Swain Monali, Rane Pallavi, Pantvaidya Gouri, Nair Sudhir, Nair Deepa, Deshmukh Anuja, Thiagarajan Shivakumar, Vaish Richa, Tuljapurkar Vidisha, Dravid Chandrashekhar, Joshi Poonam, Shetty Rathan, Singh Arjun, Chaturvedi Pankaj
Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
Cancer Med. 2025 Aug;14(15):e71134. doi: 10.1002/cam4.71134.
Perineural invasion (PNI) in oral squamous cell carcinoma (OSCC) is linked to aggressive tumour behaviour and poorer survival outcomes. Adjuvant radiotherapy (RT) is recommended for PNI-positive OSCC, but optimal RT target volume remains uncertain.
This study retrospectively analysed 103 patients with histopathologically confirmed PNI-positive OSCC treated between January 2017 and December 2023. All patients underwent surgery followed by adjuvant RT, with or without concurrent chemotherapy. Recurrence patterns were categorised as in-field, marginal or out-of-field. Survival outcomes, including overall survival (OS) and disease-free survival (DFS), were assessed using the Kaplan-Meier method, and prognostic factors were analysed using univariate and multivariate models.
The median follow-up was 22.2 months. The 2-year OS and DFS were 63% (95% CI: 53%-75%) and 57% (95% CI: 48%-68%), respectively. In-field recurrences constituted 70% of local failures, with no recurrences observed at the skull base despite conservative RT volumes. Extensive PNI, large nerve involvement and extratumoral spread were significantly associated with higher recurrence rates and poorer survival. Multivariate analysis identified advanced tumour stage (T3/T4) and extranodal extension (ENE) as independent predictors of worse OS (HR: 2.67, p = 0.016; HR: 2.08, p = 0.045, respectively), while depth of invasion (DoI) > 10 mm significantly impacted DFS (HR: 0.28, p = 0.04 for DoI ≤ 10 mm).
Our findings suggest that expanding RT volumes to cover entire cranial nerve pathways may not improve outcomes and increase the risk of toxicity. A personalised approach to RT planning, incorporating PNI extent, nerve involvement and other high-risk features, is essential for optimising treatment outcomes in PNI-positive OSCC.
口腔鳞状细胞癌(OSCC)中的神经周围浸润(PNI)与肿瘤侵袭性和较差的生存结果相关。对于PNI阳性的OSCC,推荐辅助放疗(RT),但最佳放疗靶区体积仍不确定。
本研究回顾性分析了2017年1月至2023年12月期间接受治疗的103例经组织病理学证实为PNI阳性的OSCC患者。所有患者均接受手术,随后进行辅助放疗,可联合或不联合同步化疗。复发模式分为野内、边缘或野外。采用Kaplan-Meier法评估总生存(OS)和无病生存(DFS)等生存结果,并使用单因素和多因素模型分析预后因素。
中位随访时间为22.2个月。2年总生存率和无病生存率分别为63%(95%CI:53%-75%)和57%(95%CI:48%-68%)。野内复发占局部失败的70%,尽管放疗靶区保守,但未观察到颅底复发。广泛的PNI、大神经受累和肿瘤外扩散与较高的复发率和较差的生存显著相关。多因素分析确定晚期肿瘤分期(T3/T4)和结外扩展(ENE)是总生存较差的独立预测因素(HR:2.67,p = 0.016;HR:2.08,p = 0.045),而浸润深度(DoI)>10 mm对无病生存有显著影响(DoI≤10 mm时HR:0.28,p = 0.04)。
我们的研究结果表明,扩大放疗靶区以覆盖整个颅神经通路可能不会改善预后,反而会增加毒性风险。采用个性化的放疗计划方法,纳入PNI范围、神经受累情况和其他高危特征,对于优化PNI阳性OSCC的治疗结果至关重要。